Literature DB >> 15170678

HPV-18 E6*I modulates HPV-18 full-length E6 functions in a cell cycle dependent manner.

Ernesto Guccione1, David Pim, Lawrence Banks.   

Abstract

The E6 ORFs of the high-risk Human Papillomavirus (HPV) Types 16 and 18 have been shown to encode (besides the full-length product) several truncated forms, termed E6*. We have reported previously that the HPV-18 E6*I protein interacts with the full-length E6 protein as well as with the ubiquitin ligase E6-AP and, as a result of this, E6* can inhibit E6-mediated degradation of p53. Moreover, ectopic expression of the HPV-18 E6*I protein has an antiproliferative effect in cervical cancer-derived cell lines. These results led us to investigate further the modulatory functions of E6*I on E6. Using epitope tagged versions of the 2 proteins we have analyzed the sub-cellular distribution of the full-length HPV18 E6 and HPV18 E6*I, as well as their respective cellular abundance during the cell cycle, and show specific upregulation of E6*I during G2/M. We also investigated the effect of E6*I overexpression in cell lines derived from cervical tumors, with respect to the expression levels of E6 target proteins, such as p53, hDlg and Scribble and find a corresponding increase in p53 expression also during G2/M. In addition we show that the overexpression of E6*I reduces the amount of E6 in the insoluble nuclear and membrane fractions of the cell. E6 levels can, however, be restored by the addition of a specific proteasome inhibitor, suggesting that the interaction between E6 and E6*I leads to the destabilization of a subset of the E6 protein. These results suggest that the E6*I protein can function as a fine regulator of the full-length E6 protein by direct interaction that leads both to changes in its cellular abundance as well as its distribution during particular phases of the cell cycle. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15170678     DOI: 10.1002/ijc.20184

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress.

Authors:  Vonetta M Williams; Maria Filippova; Ubaldo Soto; Penelope J Duerksen-Hughes
Journal:  Future Virol       Date:  2011-01-01       Impact factor: 1.831

2.  The small splice variant of HPV16 E6, E6, reduces tumor formation in cervical carcinoma xenografts.

Authors:  Maria Filippova; Whitney Evans; Robert Aragon; Valery Filippov; Vonetta M Williams; Linda Hong; Mark E Reeves; Penelope Duerksen-Hughes
Journal:  Virology       Date:  2014-01-01       Impact factor: 3.616

3.  The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity.

Authors:  Maria Filippova; Melyssa M Johnson; Marnelli Bautista; Valery Filippov; Nadja Fodor; Sandy S Tungteakkhun; Kadia Williams; Penelope J Duerksen-Hughes
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

Review 4.  High-Risk Human Papillomavirus Oncogenic E6/E7 mRNAs Splicing Regulation.

Authors:  Yunji Zheng; Xue Li; Yisheng Jiao; Chengjun Wu
Journal:  Front Cell Infect Microbiol       Date:  2022-06-27       Impact factor: 6.073

5.  A Critical Role for p53 during the HPV16 Life Cycle.

Authors:  Christian T Fontan; Claire D James; Apurva T Prabhakar; Molly L Bristol; Raymonde Otoa; Xu Wang; Elmira Karimi; Pavithra Rajagopalan; Devraj Basu; Iain M Morgan
Journal:  Microbiol Spectr       Date:  2022-05-24

6.  Human papillomavirus (HPV)-18 E6 oncoprotein interferes with the epithelial cell polarity Par3 protein.

Authors:  Florencia Facciuto; Marina Bugnon Valdano; Federico Marziali; Paola Massimi; Lawrence Banks; Ana Laura Cavatorta; Daniela Gardiol
Journal:  Mol Oncol       Date:  2014-01-14       Impact factor: 6.603

7.  PATJ, a tight junction-associated PDZ protein, is a novel degradation target of high-risk human papillomavirus E6 and the alternatively spliced isoform 18 E6.

Authors:  Carina H Storrs; Saul J Silverstein
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

8.  The human papillomavirus (HPV) E6* proteins from high-risk, mucosal HPVs can direct degradation of cellular proteins in the absence of full-length E6 protein.

Authors:  David Pim; Vjekoslav Tomaic; Lawrence Banks
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

9.  Complexes of human papillomavirus type 16 E6 proteins form pseudo-death-inducing signaling complex structures during tumor necrosis factor-mediated apoptosis.

Authors:  Maria Filippova; Valery A Filippov; Mercy Kagoda; Theodore Garnett; Nadya Fodor; Penelope J Duerksen-Hughes
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

10.  Differential localization of HPV16 E6 splice products with E6-associated protein.

Authors:  Kulthida Vaeteewoottacharn; Siriphatr Chamutpong; Mathurose Ponglikitmongkol; Peter C Angeletti
Journal:  Virol J       Date:  2005-06-16       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.